Molecular Pathologist
Tempus AI
Summary
Passionate about precision medicine and advancing the healthcare industry? Recent advancements in underlying technology have finally made it possible for AI to impact clinical care in a meaningful way. Tempus' proprietary platform connects an entire ecosystem of real-world evidence to deliver real-time, actionable insights to physicians, providing critical information about the right treatments for the right patients, at the right time.
Job description
What you'll do:
- Evaluate NGS sequencing results
- Conduct pathology review (H&E and IHC) for clinical and research specimens
- Participate in clinical report review and delivery
- Collaborate with multi-disciplinary team focused on answering key biological questions
- Work to maintain CLIA/CAP compliance
Preferred Qualifications:
- MD with current medical license (IL licensure to be obtained prior to start date)
- Board certified/eligible in Molecular Genetic Pathology
- American Board of Pathology Certification in Anatomic and/or Clinical Pathology
- Clinical experience with next generation sequencing interpretation
- Knowledge and/or experience in oncology, cancer immunotherapy, medical immunology and clinical research, preferred
- Excellent managerial, organizational, reporting and communication skills
- Experience ensuring compliance of a clinical laboratory to regulatory standards
- Experience working in a regulated clinical laboratory environment (CLIA/CAP/NYSDOH/QSR)
Requirements
- MD with current medical license (IL licensure to be obtained prior to start date)
- Board certified/eligible in Molecular Genetic Pathology
- American Board of Pathology Certification in Anatomic and/or Clinical Pathology
- Clinical experience with next generation sequencing interpretation
- Knowledge and/or experience in oncology, cancer immunotherapy, medical immunology and clinical research, preferred
- Excellent managerial, organizational, reporting and communication skills
- Experience ensuring compliance of a clinical laboratory to regulatory standards
- Experience working in a regulated clinical laboratory environment (CLIA/CAP/NYSDOH/QSR)
Benefits
- Incentive compensation
- Restricted stock units
- Medical benefits
Company overview
Tempus AI, Inc. (NASDAQ: TEM) is a pioneering healthcare technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. The company was established after Lefkofsky's wife was diagnosed with breast cancer, driving his mission to revolutionize cancer care through technology and artificial intelligence. Tempus specializes in applying AI to advance precision medicine by collecting and analyzing vast amounts of molecular, clinical, and genomic data. The company operates across multiple therapeutic areas including oncology, cardiology, radiology, neurology, psychiatry, and dermatology. Tempus provides comprehensive diagnostic services including next-generation sequencing (NGS), PCR profiling, and molecular pathology testing. Its AI-powered platform enables physicians to make real-time, data-driven decisions for personalized patient care and targeted therapies. The company went public in June 2024 and has expanded globally with operations in multiple countries. Tempus continues to innovate at the intersection of healthcare and artificial intelligence, aiming to ensure patients receive the right treatments at the right time for improved health outcomes.